TRPV4 and heart failure: Interestingly, a recent clinical study in patients with stable heart failure found that the novel, first-in-class TRPV4 inhibitor GSK2798745 was well tolerated, suggesting that TRPV4 blockade might be a safe target for metastatic breast cancer [198].